April 4, 2025 - 02:54
I-Mab has reported continued positive momentum in its Phase 1b combination trial of givastomig for first-line gastric cancer. The company anticipates topline dose escalation data from this trial, which involves 17 participants, to be released in the second half of 2025. This promising development highlights the potential of givastomig as a treatment option in this challenging area of oncology.
Moreover, enrollment for the first dose expansion cohort of the trial has been completed ahead of schedule, indicating robust interest and engagement in the study. The ongoing efforts in the second expansion cohort further demonstrate the commitment to advancing this important research.
Financially, I-Mab is in a strong position, reporting $173.4 million in cash, cash equivalents, and short-term investments as of December 31, 2024. This financial stability provides a runway into 2027, supporting the company through anticipated clinical readouts and ensuring continued progress in its innovative therapies.
